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Introduction 
Since its first use by Kistiakowsky and Cramer in 
1941 [1], [11C]cyanide has been a useful and 
versatile radiochemical synthon for a wide varie-
ty of reactions.  It has been used as a nucleo-
philic precursor for deoxyglucose [2–5], glucose 
[6], lactic [1, 7–10] and pyruvic [10, 11] acids, 
putrescine [12] and its enzymatic-precursor 
ornithine [13], fatty acids [14] and amines [15], 
spiroperidol [16], dimethyoxyphenethylamine 
[17], γ-vinyl-γ-aminobutyric acid [18], and [1-
11C]- [19–29], [4-11C]- [30–32], and [5-11C]-
labeled [32, 33] amino acids.  It has also been 
used to produce the electrophilic nitrilation 
precursor [11C]cyanogen bromide [34], which 
has been used to label a variety of small mole-
cules [35–38], polysacchirides [39] and proteins 
[40].  Most recently, the [11C]cyanide precursor 
has found significant use in transition metal (Pd, 
Cu) catalyzed aryl nitrilation reactions [41–50].  
In the vast majority of these synthesis proce-
dures, 11C is initially produced by cyclotron irra-
diation of a N2 / O2 gas target, producing 
[11C]CO2, which is then converted to [
11C]CH4 
over hot nickel catalyst, then combined with NH3 
and converted to [11C]cyanide over hot platinum 
catalyst, most commonly citing two detailed 
literature references [20, 51].  However, despite 
its position as rote gas-phase product, the cata-
lytic synthesis of [11C]cyanide is difficult to opti-
mize and often only perfunctorily discussed in 
the radiochemical literature. 
Recently, [11C]CN– has also been used in the 
synthesis of plant hormones, such as indole-3-
[1-11C]acetic acid ([11C]IAA) [52–54], for in vivo 
mechanistic studies of plant physiology using 
PET imaging.  IAA is the principal phytohormone 
implicated in a wide variety of growth and de-
velopment functions in plants, including stem 
elongation, response to light and gravity, and 
vasculature, lateral root, and organ formation 
[55].  The University of Wisconsin has expertise 
in cyclotron production and radiochemistry of 
11C and previous experience in the PET imaging 
of plants [56,57].  In the present work, we have 
worked to optimize [11C]CN– production for the 
synthesis of [11C]IAA and the PET imaging of 
auxin transport in living plants. 
 
Material and Methods 
Compressed gases, including 99.999% He, 
99.995% NH3, and 99.9999% purity 90% N2 / 
10% H2, from Airgas, platinum wire (99.99%, 
Strem Chemicals), ~60 mesh platinum sponge 
(99.98%, Alfa Aesar), gramine (99%, ACROS Or-
ganics), DMSO (silylation grade, Thermo Scien-
tific), and other chemicals (at least ACS reagent 
grade) were used in this work.  Preparative high-
performance liquid chromatography (HPLC) was 
performed with an Rainin Instrument Co Inc 
HPXL solvent pump, Phenomenex Luna C18 
250 x 10 mm (10 µm beads) column, Applied 
Biosystems model 785A absorbance detector, 
Carrol & Ramsey Associates model 105-S radia-
tion detector, and PowerChrome model 280 
eDAQ.  Analytical HPLC was performed with a 
Waters system including two model 515 pumps, 
a Pump Control Module II, a model 2489 ab-
sorbance detector, an e-SAT/IN data acquisition 
module, a Carrol & Ramsey Associates model 
105-S radiation detector, and a Phenomenex 
Kinetex C18 75 x 4.6 mm (2.6 µm beads) column.   
[11C]CH4 was produced by irradiating 270 psi 
of 90% N2, 10% H2 with 30 µA of 16.1 MeV pro-
tons from a GE PETtrace cyclotron.  After irradia-
tion, the [11C]CH4 was converted to [
11C]CN– by 
passing through a quartz tube containing 3.0 g of 
Pt wire and powder between quartz wool frits 
inside a 1000 ˚C Carbolite tube furnace.  The 
constituents and flow rate of the [11C]CH4 carrier 
gas were varied in an effort to optimize the 
oven's catalytic production of [11C]CN– from CH4 
and NH3.  The following conditions were investi-
gated: 
i. Directly flowing irradiated target gas ver-
sus trapping, purging and releasing 
[11C]CH4 from a -178 ˚C HayeSep D column 
in He through the Pt furnace.   
ii. Varying the amount of NH3 mixed with 
the [11C]CH4 carrier gas prior to the Pt 
furnace.  
iii. Varying the purity of the added NH3 gas 
with the addition of a hydride gas purifier 
(Entegris model 35KF), reducing O2 and 
H2O impurities to <12ppb. 
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iv. Varying the flow rate of He gas carrying 
trapped, purged and released [11C]CH4.   
After flowing through the Pt furnace, the gas 
stream was bubbled through 300 µL of DMSO 
containing IAA precursor gramine (1mg), then 
passed through a 60cm x 5 cm column contain-
ing ascarite to absorb [11C]CO2, followed by 
a -178˚C Porapak Q column to trap [11C]CH4 and 
[11C]CO, as shown in FIG. 1. 
 
FIGURE 1. Simplified schematic of [11C]CN– pro-
duction and synthesis system. 
After bubbling, the DMSO/gramine vial was 
heated to 140 ˚C to react the gramine with 
[11C]CN–, forming the intermediate indole-3-[1-
11C]acetonitrile ([11C]IAN), which was subse-
quently purified by solid phase extraction (SPE).  
The reaction mixture was diluted into 20 mL 
water and loaded onto a preconditioned (2 mL 
ethanol, 10 mL H2O) Waters Sep-Pak light C18 
cartridge, followed by rinsing with 5 mL 99 : 1 :: 
0.1% HCl : acetonitrile and 10 mL 95 : 5 :: 0.1% 
HCl : acetonitrile, and eluted with 0.5 mL diethyl 
ether.  The ether was subsequently evaporated 
under argon flow, followed by the hydrolysis of 
[11C]IAN to [11C]IAA with the addition of 300 µL 
1 M NaOH and heating to 140 ˚C for 5 minutes.   
After hydrolysis, the solution was neutralized 
with 300 µL 1 M HCl and purified using prepara-
tive HPLC with a mobile phase composition of 35 
: 65 :: acetonitrile : 0.1% formic acid in H2O and 
flow rate of 3 mL/min.  The [11C]IAA peak, elut-
ing at 13 minutes, was collected and rotary 
evaporated to dryness, then again after the 
addition of 5 mL acetonitrile, followed by its 
reconstitution in 50 µL of water.  Analytical HPLC 
was performed on the [11C]IAA before and after 
this evaporation procedure with a linear gradi-
ent elution over 20 minutes of 10 : 90 - 30 : 70 :: 
acetonitrile : 0.1% formic acid and a 1 mL/min 
flow rate, eluting at 7.6 minutes. 
 
Results and Conclusion 
Optimization of the [11C]CN– gas phase chemistry 
was performed using two key metrics for meas-
uring conversion yield.  First is the fraction of 
total produced radioactivity that trapped in the 
DMSO/gramine solution (denoted %DMSO), and 
second, the fraction of DMSO/gramine-trapped 
activity that was able to react with gramine to 
form [11C]IAN (denoted %IAN).  The former of 
these metrics was measured by ionization 
chamber measurements of the reaction vial and 
ascarite and Poropak Q traps.  Under certain 
conditions, significant losses were experienced 
in this step due to unconverted [11C]CH4 or 
through combustion, forming [11C]CO2 or 
[11C]CO.  The latter metric was measured by SPE 
or preparative HPLC of [11C]IAN and experienced 
losses due to production of incomplete oxida-
tion products of the CH4-NH3 reaction, such as 
methylamine.    Total [11C]CH4 to [
11C]CN– con-
version yields (%CN–) were reported by the 
product of the two metrics. 
It was initially hypothesized that the irradia-
tion of a 90% N2, 10% H2 target gas would pro-
duce sufficient in-target-hot-atom-produced NH3 
to convert [11C]CH4
 to [11C]CN– in the Pt furnace.  
However, conversion yields were found to be 
low and highly variable, as shown in the top line 
of TABLE 1.  While in disagreement with previous 
reports [51], this is likely as a result the batch 
irradiation conditions resulting in ammonia 
losses in the target chamber and along the tub-
ing walls.   
 
[11C]CH4 carrier 
gas composition %DMSO %IAN  %CN
– 
~100 mL/min 
H2/N2.
 
(13±8)
% 
(n=14) 
(9 
±16)% 
(n=15) 
(0.7 
±0.8)% 
(n=13) 
~100 mL/min 
H2/N2, ~12 
mL/min NH3.
 
(37 
±10)% 
(n=17) 
(22 
±9)% 
(n=17) 
(8±3)% 
(n=17) 
100 mL/min He, 
~10 mL/min NH3. 
~2%  
(n=1) n/a n/a 
40 mL/min He, 
~10 mL/min NH3. 
~2%  
(n=1) n/a n/a 
20 mL/min He, 
~10 mL/min NH3
. 
(40 
±18)% 
(n=5) 
(44 
±21)% 
(n=5) 
(16 
±7)% 
(n=5) 
20 mL/min He, (42 (59 (24 
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~20 mL/min NH3
. ±27)% 
(n=5) 
±18)%       
(n=5) 
±17)% 
(n=5) 
20 mL/min He, 
30 - 40 mL/min 
NH3
. 
(74±7)
% 
(n=11) 
(50 
±15)% 
(n=11) 
(40 
±14)% 
(n=11) 
TABLE 1. [11C]CH4 to [
11C]CN– conversion yields. 
[11C]CN– yields and reproducibility were im-
proved when combining the target gas with a 
stream of anhydrous NH3 gas flow with conver-
sion yields reported in the second line of TABLE 1.  
However, these yields remained undesirably 
low, potentially as a result of the 10% H2 carrier 
gas having an adverse effect on the oxidative 
conversion of [11C]CH4 to [
11C]CN–.  To remedy 
this, the irradiated target gas was trapped, 
purged, released in He and combined with NH3 
gas before flowing through the Pt furnace.  Ini-
tial experiments using 99.995% anhydrous NH3 
gas resulted in very poor (<0.1%) [11C]CN– yields 
as a result of nearly quantitative combustion 
forming [11C]CO2.  Installation of a hydride gas 
purifier to reduce O2 and H2O impurities in NH3 
below 12 ppb improved yields for [11C]CH4 in He, 
but did not significantly affect those from 
[11C]CH4 in N2/H2 target gas. 
Flow rates of He and purified NH3 carrying 
[11C]CH4 through the platinum oven were opti-
mized to maximize %CN– yield.  Initial experi-
ments determined that conversion yields were 
highly sensitive to [11C]CH4 carrier gas flow rate, 
with lower flow rates giving higher yields, as 
shown in lines 3 – 5 of TABLE 1.  This result is in 
disagreement with Iwata et al. that report that 
[11C]CN– yield decreases with flow rates below 
100 mL/min [20].  The %CN– yield was also found 
to be dependent on the flow rate of NH3 with 
higher flow resulting in higher yields, shown in 
lines 5 – 7 of TABLE 1.  This trend was observed 
by Iwata et al., but on a significantly different 
scale, where CN– yields plateaued above only 1% 
NH3 concentration by volume.  In the present 
work, the catalytic production of [11C]CN– re-
quired a drastically higher fraction of the carrier 
gas to be NH3.  These notable discrepancies with 
previously published work imply that optimiza-
tion of [11C]CN– production yields is very sensi-
tive to different experimental apparatuses, car-
rier gas compositions, and flow rates.   
Full [11C]IAA synthesis chemistries, including 
preparative HPLC, reconstitution in 50 µL of H2O, 
and analytical HPLC, were performed utilizing 
[11C]CN– produced through a variety of the 
above discussed carrier gas compositions, with 
the majority using ~100 mL/min H2/N2, ~12 
mL/min NH3. The decay-corrected to end-of-
bombardment radiochemical yield for [11C]IAA in 
50 µL H2O was (2.6±1.1)% of the total produced 
11CH4 (n=14), with total synthesis time of 62±5 
minutes.  The subset of experiments utilizing the 
improved [11C]CN– production conditions result-
ing from 20 mL/min He, 30 - 40 mL/min NH3
 
carrier gas compositions showed only slightly 
improved radiochemical yields of (4±2)% (n=3).  
The most significant radiochemical losses were 
during the SPE procedure and in the reconstitu-
tion of the final [11C]IAA product in 50 µL of H2O.  
Representative results from 254 nm absorbance 
detectors and radiation detectors after prepara-
tive and analytical HLPC are shown in FIG. 2 and 
FIG. 3, respectively.  The radioactive impurity 
eluting at 8 minutes from preparative HPLC was 
identified as indole-3-[1-11C]acetamide, the 
incomplete hydrolysis product of [11C]IAN.  The 
only significant cold impurity co-eluting from 
preparative HPLC with [11C]IAA was identified as 
indole-3-carboxylic acid, the hydrolysis product 
of gramine.  Specific activities of [11C]IAA were 
measured to be ~30 MBq/nmol, decay-corrected 
to end-of-bombardment. 
 
FIGURE 2. Relative absorbance and radioactivity 
eluting from preparative HPLC.   
FIGURE 3. Relative absorbance and radioactivity 
eluting from analytical HLPLC.  
This synthesis procedure allowed for the 
production of suitable quantities of [11C]IAA for 
monitoring auxin distribution and transport in 
the model organism rapid-cycling Brassica 
oleracea (rcBo) [58] using a Siemens microPET 
P4 scanner.  In these experiments, 0.7 ─ 10 MBq 
of [11C]IAA was administered as a bolus to the 
severed petiole of rcBo in 3 ─ 10 µL of H2O at the 
start of a 90 minute PET scan.  Transport was 
0
20
40
60
80
100
0 10 20 30
Re
la
tiv
e 
si
gn
al
 
Time (min) 
Abs. (254 nm)
Radioactivity
1Corresponding author, E-mail: paellison@wisc.edu 
compared following administration to the first 
true leaf versus the final fully formed leaf in 
plants with and without exposure to the polar 
auxin transport inhibitor naphthylphthalamic 
acid (NPA).  Results of these experiments will be 
reported in a forthcoming manuscript. 
In conclusion, the Pt-catalyzed oxidative 
conversion of [11C]CH4 and NH3 to [
11C]CN– is a 
challenging process to optimize and highly sensi-
tive to carrier gas composition and flow rate.  
Optimization for our experimental conditions 
yielded several results which disagreed with 
previous reports.  [11C]IAA produced using 
[11C]CN– is well suited for PET imaging of polar 
auxin transport in living plants.  
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